The combined value of the top five pharma M&A deals stood at $91.56bn.

Total pharma industry deals for Q1 2019 worth $143.29bn were announced globally, according to GlobalData’s deals database.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all
  • Embed this chart

    Embed this chart into your website

    Copy and paste the code below into your website to display the chart.

The value marked a decrease of 40.6% over the previous quarter and a rise of 139.3% when compared with the last four-quarter average of $59.88bn.

In terms of number of deals, the sector saw a drop of 5.9% over the last four-quarter average with 384 deals against the average of 408 deals.

In value terms, North America led the activity with deals worth $133.38bn.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Pharma industry deals in Q1 2019: Top deals

The top five pharma deals accounted for 87.4% of the overall value during Q1 2019.

The combined value of the top five pharma deals stood at $125.17bn, against the overall value of $143.29bn recorded for the quarter. The top announced pharma deal tracked by GlobalData in Q1 2019 was Bristol-Myers Squibb‘s $89.54bn acquisition of Celgene.

In second place was the $21.4bn asset transaction with General Electric by Danaher and in third place was Eli Lilly’s $8bn acquisition of Loxo Oncology.

The $4.3bn acquisition of Spark Therapeutics by F. Hoffmann-La Roche and Grifols‘ stake acquisition of Shanghai RAAS Blood Products for $1.93bn held fourth and fifth positions, respectively.

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.